Group 1 - The company has received the CBPF-GMP certificate from Brazil's National Health Surveillance Agency (ANVISA), confirming compliance with international production quality management standards [1] - The cGMP inspection covered the company's production line for active pharmaceutical ingredients Semaglutide and Liraglutide, marking the third successful overseas compliance check after approvals from the FDA and MFDS [1] - This certification is expected to enhance the company's ability to promote and sell its products in international markets [1] Group 2 - The cGMP inspection took place from April 28 to May 2, 2025, at the company's facility located at 28 Linpu Road, Lianyungang Economic and Technological Development Zone [2] - The inspection concluded that the company meets cGMP standards, which is crucial for exporting active pharmaceutical ingredients [2]
江苏诺泰澳赛诺生物制药股份有限公司关于自愿披露通过药品cGMP现场检查的公告